Inactive Instrument

Novartis AG Stock Swiss Exchange

Equities

CH0012005267

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Novartis AG

Financials

Sales 2024 * 49.13B 44.13B 67.19B Sales 2025 * 51.26B 46.05B 70.11B Capitalization 218B 196B 299B
Net income 2024 * 10.45B 9.39B 14.29B Net income 2025 * 11.7B 10.51B 16B EV / Sales 2024 * 4.7 x
Net Debt 2024 * 12.71B 11.42B 17.39B Net Debt 2025 * 10.76B 9.67B 14.72B EV / Sales 2025 * 4.47 x
P/E ratio 2024 *
20.9 x
P/E ratio 2025 *
18.1 x
Employees -
Yield 2024 *
3.41%
Yield 2025 *
3.54%
Free-Float 85.22%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company